GEN Exclusives

More »

GEN News Highlights

More »
May 14, 2007

Stallergenes and CMC Biopharmaceuticals Collaborate to Advance Allergy Drug

  • Stallergenes and CMC Biopharmaceuticals inked an agreement for development and supply of recombinant Bet v 1 (rBet v 1) purified bulk. The product is the protein that embodies most of the allergenicity of birch pollen, according to Stallergenes.

    Scale up the manufacturing of GMP purified recombinant Bet v 1 will be undertaken by CMC Biopharmaceuticals. The company also will produce batches for Phase III trials and commercial supply.

    “This agreement will speed our ORALAIR® Bet v 1 project towards late-stage clinical trials and registration while securing the supply of active ingredients for commercial batches,” remarks Albert Saporta, chairman and CEO of Stallergenes.

    Stallergenes reports that it has carried out a proof-of-concept trial aimed at demonstrating the ability of Bet v 1 to reduce the symptoms in patients allergic to birch pollen. This double-blind, placebo-controlled study conducted in 150 patients in five countries was highly significant in efficacy and has also shown a good safety profile in the rBet v 1 group versus placebo, similar to the natural extract group, says the firm.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?